Dr. Howard McLeod is Medical Director for Precision Medicine at The Geriatric Oncology Consortium, a fellow of the American Society of Clinical Oncology and has worked on research projects with some of the most notable institutions around the world, including FDA, NIH, and NCI.

We cover a lot of ground with Dr. McLeod in this podcast, including career advice, the advancement of precision medicine technology and the positive impact of COVID on telemedicine and clinical trials. Read the full summary and tune in to the audio here.

Bill Bonello, president of NeoGenomics Informatics, and Clynt Taylor, president of Trapelo Health, discuss challenges in precision medicine and how evidence-based technologies can help deliver more appropriate, value-based care to more patients.

As a subtext to the discussion is the recent acquisition of Trapelo Health, creator of clinical decision-making platform Trapelo, by NeoGenomics Informatics, provider of bioinformatics services. This acquisition is aimed at improving access to precision medicine testing and treatment. Read the full summary and learn more about Trapelo here.

In this notable episode, Dr. Caroline Carney, Chief Medical Officer at Magellan Health, and Clynt Taylor, CEO at Trapelo Health, join us to discuss how collaborative technologies can help payers more effectively manage the cost of precision oncology while delivering the best outcomes for patients. Read the full summary.

In this episode, Dr. F. Anthony Greco, medical oncologist at Tennessee Oncology, discusses the role that precision medicine has played in improving our diagnosis and treatment of cancer.

In this Part 2 podcast featuring Dr. Gabriel A. Bien-Willner, Medical Director of the MolDX programat Palmetto GBA, we dive into the core challenges that payers face in navigating the explosion of precision medicine tests and treatments, and specifically how the prior authorization process can be streamlined by keeping payers updated on changes in coverage policy for new genes or CDx.

Be sure to tune in to Part 1 with Dr. Bien-Willner who speaks about reshaping reimbursement policies for genetic and genomic testing.

Christopher Boone, Vice President and Global Head of Health Economics & Outcomes Research at AbbVie, shares his thoughts on how using data to understand a patient’s real-world environment can expand the practice of Precision Medicine.

It is fitting that our first guests on Season 3 of the Precision Medicine Podcast are Rob Metcalf, CEO of Concert Genetics and Clynt Taylor, CEO of Trapelo Health who are both innovators in precision medicine technology. What we learn from them in this episode is that after 20 years of hearing about the “promise of precision medicine,” technology has reached a critical point where it can begin to accelerate that progress. Read the full summary, listen and learn more here.

In this episode, and in honor of lung cancer awareness month we had the opportunity to speak with Dr. Luis Raez, Medical Director and Chief of Hematology Oncology at Memorial Cancer Institute who focuses on treating lung cancer. Hear how the emergence of next-generation sequencing has changed his approach to lung cancer treatment, what notable discoveries in lung cancer have occurred over the last year, and how he sees COVID-19 impacting the treatment of cancer. Tune in to the full episode here.

In the first of a two-part podcast, Gabriel A. Bien-Willner MD, PhD, FCAP, Medical Director at MolDX, and Chief Medical Officer at Palmetto GBA shares how he has helped implement payer controls and coverage and set policies for affiliated Medicare Administrative Contractors in 28 states.

In the past, payers have had to navigate the growing field of precision medicine without the benefit of expertise, so their only guidance came from the NCCN or consultations with other experts in the field. Today, under his direction, Palmetto GBA is able to base its policies on evidentiary reviews, and he believes this form of evidence-based decision-making should be an industrywide standard.

Dr. Mark Moasser, a physician-scientist and breast cancer specialist at the University of California, San Francisco discusses his research focus on the HER2 oncogene, the latest trial findings and the importance of improving patient access to clinical trials.

At Trapelo, connecting oncologists with patient-appropriate clinical trials is a major part of our mission, so we were grateful for the opportunity to talk to Dr. Moasser and learn more about his thoughts on this matter. Tune in to the full episode to learn more about his current research and perspective on the future of precision medicine.